Wedbush reissued their outperform rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a research report report published on Friday,Benzinga reports. Wedbush currently has a $4.00 target price on the stock.
Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $9.20.
Get Our Latest Report on Gossamer Bio
Gossamer Bio Trading Up 11.5 %
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). On average, equities analysts expect that Gossamer Bio will post -0.28 earnings per share for the current year.
Institutional Investors Weigh In On Gossamer Bio
A number of hedge funds have recently bought and sold shares of the stock. Graham Capital Management L.P. acquired a new position in shares of Gossamer Bio during the fourth quarter worth about $32,000. US Bancorp DE purchased a new position in Gossamer Bio in the third quarter worth approximately $39,000. Fullcircle Wealth LLC acquired a new position in Gossamer Bio during the 4th quarter worth approximately $43,000. GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio in the 3rd quarter valued at approximately $67,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Gossamer Bio in the 4th quarter valued at approximately $68,000. Institutional investors and hedge funds own 81.23% of the company’s stock.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Featured Stories
- Five stocks we like better than Gossamer Bio
- What Are the FAANG Stocks and Are They Good Investments?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Transportation Stocks Investing
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- 3 Stocks to Consider Buying in October
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.